Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Southeast Asia’s first helicopter flight using sustainable aviation fuel takes off from Seletar Airport in Singapore

Neste Corporation, Press Release, 26 September 2022 at 11:00 a.m. (EET) Delegations from Neste, Bell and SafranToday, Bell’s next generation five seater helicopter, the Bell 505, fueled with Neste MY Sustainable Aviation Fuel ™  (SAF) took off at Seletar Airport in Singapore for a demonstration flight. This is the first ever helicopter flight fueled with SAF in Southeast Asia.This remarkable milestone was achieved by a close cooperation between Bell, Safran

Nomination Committee for SEB appointed

Skandinaviska Enskilda Banken AB's Annual General Meeting will be held on Tuesday, 4 April, 2023. The members of SEB's Nomination Committee are:Petra Hedengran, Investor, ChairmanMagnus Billing, Alecta   Johan Sidenmark, AMF Lars Heikensten, Trygg-StiftelsenMarcus Wallenberg, Chairman of the Board, SEB The shareholders having appointed members of the Nomination Committee together represent approximately 35,4 per cent of the voting rights for all shares in the bank. The Board of SEB has appointed Lars Ottersgård additional member of the Committee.  The Nomination

New scientific paper shows OssDsign Cranial PSI results with zero implant-related complications and positive treatment outcomes in largest US case series to date

Uppsala, Sweden, September 26, 2022. OssDsign AB (publ.) today announces that an independent clinical research team in New York, U.S., lead by Ralph Rahme, M.D., F.A.C.S., has published their clinical findings, describing treatment outcomes with OssDsign PSI in the largest U.S. cohort to date. The study included 18 patients who underwent cranioplasty, showing that the procedure was successful in all cases, and that no implant-related complications occurred during a 6-month median follow-up period. The clinical paper is published in the journal World Neurosurgery.OssDsign Cranial PSI is a

Wallenstam announces tender offer regarding out-standing SEK bonds maturing on 23 November 2022

Wallenstam AB (publ) (the “Issuer” or ”Wallenstam”) has mandated Nordea Bank Abp to act as Dealer Manager for the tender offer below. Wallenstam is offering holders of the Issuer’s outstanding floating rate senior unsecured bonds with maturity on 23 November 2022, with outstanding amount of SEK 250 million (ISIN: SE0010598870) (the ”Notes”),  to tender any and all of their Notes for purchase by the Issuer for cash (“Tender Offer”) at a price of 99.90 percent of the nominal amount, in addition to accrued and un-paid interest. The Notes will be repurchased subject to the terms and

BioStock Investor Meeting: Interview with Idogen

In connection with BioStock Investor Meeting in Stockholm, BioStock took the opportunity to interview Christina Herder, Idogen’s newly appointed interim CEO. In addition to telling us about the upcoming phase I/IIa study with the main candidate IDO8, Herder also discussed the potential of the company’s other two projects, IDO AID and IDO T.See the Interview with Idogens interim CEO Christina Herder on biostock.se: https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-idogen  This is a press release from BioStock –

Vestas secures order for 66 MW repowering project in Germany

News release from Vestas Northern and Central EuropeHamburg, 26 September 2022 Vestas has received an order of 66 MW for repowering the Lensahner Berg/Gaarz wind farm in the northeast of Schleswig-Holstein. The order is placed by four customers; Gaarz IV Windkraft GmbH & Co. KG, and three smaller project companies. Leveraging the versatility and strong performance of the EnVentus platform technology, the project includes 11 V162-6.2 MW turbines in 6.0 MW operating mode with 119m towers in combination with a 25-year full maintenance contract (AOM 5000) to maximise annual energy

Q-Free: Major Traffic Management software contract in the USA – 48 MNOK

North Carolina Department of Transportation has awarded Q-Free a state-wide traffic controller software contract in the USA totalling minimum 48 MNOK. The contract includes delivery of Q-Free’s MAXTIME and Kinetic Signals solutions. The contract includes licences and a 7-year maintenance period. – We are very pleased to see that Q-Free was evaluated against the competition and selected as the best solution for NCDOT’s Statewide traffic management needs. The contract expands our presence in the South-eastern United States and provides us with an opportunity to sell additional Kinetic

Enersense International Plc – Managers’ transactions – Juha Silvola

Enersense International PlcStock Exchange Release, 26 September 2022 at 10:10 a.m.Person subject to the notification requirement Name: Silvola, Juha Position: Other senior manager Issuer: Enersense International Plc LEI: 743700XSMVPR48XIML56 Notification type: INITIAL NOTIFICATION Reference number: 19955/4/4 ____________________________________________ Transaction date: 2022-09-23 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000301585 Nature of the transaction: ACQUISITION Transaction details: (1): Volume: 2913 Unit price: 5.

Survey: Viking Line best in the industry in both customer satisfaction and sustainability

Of all passenger transport operators in Finland, Viking Line has the most satisfied and most loyal customers, according to EPSI Rating's survey. As travel recovers at a good pace, customers have high expectations for both service and sustainability.EPSI Rating's survey investigates customer views on passenger transport providers, such as shipping companies, airlines and bus, local transport and taxi companies. Viking Line was ranked first in both customer satisfaction and customer loyalty. "The Covid-19 pandemic had a severe impact on both operators and customers in passenger transport

Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia’s IMMray PanCan-d test

LUND, SWEDEN – Immunovia AB (Nasdaq Stockholm: IMMNOV) announced, that the Centers for Medicare & Medicaid Services (CMS) published a preliminary payment determination implying a price of $897 for the IMMray PanCan-d test. CMS is a federal agency within the United States Department of Health and Human Services that provides health coverage to more than 100 million people in the U.S. CMS sets the basis for payment for lab tests through the clinical lab free schedule (CLFS).   CMS agreed with the recommendation made by the Clinical Diagnostic Laboratory Tests (CDLT) Advisory Panel to

BioStock Investor Meeting: Interview with Brain+

CEO Kim Baden-Kristensen presented Danish Brain+ at the BioStock Investor Meeting and afterwards BioStock had a chat with him. Among other things, Baden-Kristensen talked more about how the company's digital tools will help people affected by dementia and Alzheimer's and answered the question of whether we are facing a digital revolution in healthcare.See the interview with CEO Kim Baden-Kristensen at biostock.se: https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-brain Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.

Repurchase of NCC Series B shares in week 38, 2022

During the period September 19 – September 23, 2022, NCC (LEI-code 213800WRGLW3CY4MHW53) repurchased a total of 363 543 own Series B shares (ISIN: SE0000117970) under the framework of the repurchase program that the Board have decided.The repurchases are part of the repurchase program of a maximum of 10 percent of Series B shares for a total of not more than SEK 1.5 bn that NCC announced on April 27, 2022. The repurchase program extends from May 11, 2022 until the 2023 Annual General Meeting and is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and

Third Implantation in Sheep Scheduled to Take Place in October

Press Release 26 September, 2022 During the first half of 2022, Realheart performed successful implantations of its total artificial heart in sheep. These implantations are part of a series of implants to test the clinical version of Realheart® TAH. The next implant has been scheduled to take place in October.Preparations for this third implant of the clinical Realheart® TAH version are underway and the implantation will be carried out in an animal laboratory in Belgium by three experienced heart surgeons who have also performed the first two implantations: Dr Dilek Gürsoy, Dr Joeri van

Veg of Lund signs letter of intent for production and distribution of DUG in Southeast Asia

Veg of Lund has signed a Letter of Intent (“LOI”) with DenEast Vietnam Co., Ltd. The companies will cooperate with the common goal of launching, producing and distributing Veg of Lund products under the DUG[®] brand in several countries in Southeast Asia, starting in Vietnam, Thailand and Singapore in early 2023.“The letter of intent is a step in our strategy to license the production of our proprietary foods to established players with extensive experience in premium consumer products. We look forward to working with partners who have a strong position in countries with large populations,

Karo Intressenter AB initiates compulsory redemption

On 16 August 2022, Karo Intressenter AB[1] (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the “Offer”). On 19 September 2022, Karo Intressenter announced the outcome of the Offer, that they completed the Offer and that Karo Intressenter thereby, at the time of the publication of the announcement, controlled in total approximately 93.7 percent of the total number of shares and votes in Karo Pharma. At

Update on NCC’s earnings

NCC’s operating profit for the third quarter will be negatively impacted by the economic situation, driven primarily by the asphalt operations in the Industry business area. Unrelated to this, a small number of residential projects in Sweden will also be subject to impairment as a result of inadequate project management.“The majority of our projects and businesses are performing well despite strong inflation and economic turbulence. However, the asphalt operations have faced major challenges since we have been unable to fully offset increased costs during the third quarter despite drastic

Visma to launch cash offer for House of Control

Visma has entered a transaction agreement to launch a voluntary cash offer of NOK 11.20 per share for all outstanding shares of House of Control. House of Control develops software as a service (SaaS) solutions for contract management and IFRS 16 compliance to customers across the Nordics, and its shares are admitted to trading on Oslo Euronext Growth. “House of Control delivers mission critical SaaS solutions that are highly complementary to our existing offerings, and we are very excited about this opportunity to invite them into the Visma family”, says Merete Hverven, CEO of Visma.

BioStock Investor Meeting: Interview with Cereno Scientific

Biotech Cereno Scientific develops new treatments for cardiovascular disease, the most common cause of death worldwide. The company's lead candidate CS1 targets the rare disease pulmonary arterial hypertension. CEO Sten R. Sörensen told BioStock more about Cereno Scientific's lead candidate and work during BioStock Investor Meeting.See the full interview with Cereno Scientific's CEO Sten R. Sörensen biostock.se: https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-cereno-scientific 

XNK Therapeutics to use generic name evencaleucel for lead candidate

XNK Therapeutics AB (“XNK”) today announced it will adopt the generic name evencaleucel for its lead candidate targeting multiple myeloma. Evencaleucel was recently recommended by the World Health Organization (WHO) as the International Nonproprietary Name (INN) for XNK’s leading drug candidate.“We are excited that the WHO now recognizes our leading drug candidate targeting multiple myeloma by recommending the generic name evencaleucel,” said Johan Liwing, CEO of XNK Therapeutics. “XNK recently announced that the first patient with multiple myeloma was treated in a Phase II clinical study

Castellum is among the first to receive NollCO\2\ certification

The Korsningen block project has now been completed, and Castellum is one of the first companies in the Nordics to receive a NollCO2 (ZeroCO2) certification.The Swedish Police Authority, the tenant in the project, has recently moved into the Korsningen office building in central Örebro. The main body of the house – seven storeys tall, built entirely of wood, and encompassing 6,900 square metres of lettable office space – radiates sustainability and innovation. The solar panels on the roof of the property not only supply the building with energy but also generate a surplus of renewable

Nomination committee appointed ahead of 2023 Annual General Meeting of Cloetta AB (publ)

In accordance with the decision of the Annual General Meeting, Cloetta’s nomination committee shall consist of at least four and at most six members. Cloetta hereby announces that the nomination committee now has been appointed ahead of the Annual General Meeting in April 2023.The nomination committee consists of the following members:Lars Schedin, Chairman, appointed by AB Malfors PromotorJohan Törnqvist, appointed by Ulla HåkansonVictoria Lidén, appointed by Storebrand Fonder ABMikael Norman, appointed by the Board of Cloetta AB Cloetta’s 2023 Annual General Meeting will be

Trading in Metacon AB (publ) shares begin today on the Nasdaq First North Growth Market

Metacon AB (publ) ("Metacon" or the "Company") announces that trading in the Company's shares will begin today, 26 September 2022, on the Nasdaq First North Growth Market.The shares are traded on Nasdaq First North Growth Market with unchanged ticker META and ISIN code SE0003086214. There is no offer or issuance of new shares in connection with the Company's shares being admitted to trading on the Nasdaq First North Growth Market. The shareholders of Metacon will not be required to take any action in connection with the list change. "This is a milestone for Metacon and at the same time a

Tele2 signs new agreement with Stena Fastigheter

Tele2 (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) announces it has signed a new agreement with Stena Fastigheter following a procurement process. Tele2 will deliver communication solutions to over 26,000 apartments and 2,000 commercial tenants in Sweden.The agreement Tele2 has signed with Stena Fastigheter is a combination deal that includes Tele2 consumer and business services as well as the communications operator iTUX and Tele2 IoT. The agreement runs until 2029.   - We look forward to being able to develop and offer more services to our tenants together with Tele2. Through

There are no items matching the current filter
There are no more items matching the current filter
Back to top